[ Back to EurekAlert! ] Public release date: 15-Sep-2008
[ | E-mail Share Share ]

Contact: Natalie Chung-Sayers
natalie.chung-sayers@sunnybrook.ca
416-480-4040
Sunnybrook Health Sciences Centre

Scientists pioneer new treatment for prostate cancer

Image-guided ultrasound targets cancer while sparing healthy tissue

Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.

The new treatment—magnetic resonance imaging (MRI)-guided transurethral ultrasound—uses heat from focused ultrasound to treat cancer in the prostate gland precisely while sparing the delicate noncancerous tissues around the prostate essential for healthy urinary, bowel and sexual function.

Sunnybrook researchers Dr. Michael Bronskill and Dr. Rajiv Chopra have licensed their innovation and formed Profound Medical Inc., which will develop the technology for clinical use.

Unlike surgical removal of the prostate, the treatment is minimally invasive and could be performed without a lengthy hospital stay. In preclinical studies, treatment takes less than 30 minutes. The therapy, on which clinicians at Sunnybrook will conduct preliminary testing in preparation for a clinical trial, could help limit the number of men living with the common, debilitating and often permanent side effects of surgery and radiation treatments currently used. More of these invasive therapies are being performed now because improved awareness among younger men has converged with better clinical detection tools.

Profound's clinical development is targeted at treatment that reduces the high level of incontinence and impotence associated with current, invasive treatments. The therapy involves two different and naturally incompatible technologies, ultrasound and MRI, which Bronskill and Chopra spent 10 years making compatible. "You have to make an ultrasound heating applicator work inside a magnetic resonance imager, without the two technologies interfering with each other," says Bronskill, who is a professor at the University of Toronto. "The prostate cancer site is a natural for this technology because it's surrounded by structures you want to spare."

Dr. Laurence Klotz, chief of urology at Sunnybrook Health Sciences Centre, and a professor at the University of Toronto, says that a noninvasive therapy for early, localized prostate cancer could improve the quality of life of hundreds of thousands of men. "The key to effective noninvasive treatment is accurate imaging of the target organ and of the effects of the treatment on tissue. In that respect, MR-guided ultrasound has many potential advantages over transrectal ultrasound-guided focused ultrasound, now approved for use in Canada," says Klotz.

The scientists' creation of this clinically viable product was done in a setting committed to commercialization. "At SRI, we are dedicated not only to developing new and better therapies and technologies, but also to getting those discoveries to our patients," says Dr. Michael Julius, vice-president of research at Sunnybrook. Profound Medical Inc. is the third imaging-technology company to be spun out of research at SRI in recent years. The other two are VisualSonics Inc. and Sentinelle Medical Inc.

###

The Terry Fox Foundation, Ontario Research and Development Challenge Fund and Canadian Institutes of Health Research funded early-stage development of the scientists' work. Early in 2008 the Ontario Institute for Cancer Research, which is funded by the government of Ontario, invested $500,000, which spurred venture capital interest and led to the formation of Profound.

Prostate cancer is the most common cancer among Canadian men. The Canadian Cancer Society estimates 24,700 men will be diagnosed with the disease in 2008 and 4,300 will die of it.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.